Search

Your search keyword '"LAMBILLIOTTE, ANNE"' showing total 163 results

Search Constraints

Start Over You searched for: Author "LAMBILLIOTTE, ANNE" Remove constraint Author: "LAMBILLIOTTE, ANNE"
163 results on '"LAMBILLIOTTE, ANNE"'

Search Results

1. Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads

6. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma

7. Autoimmune cytopenia and Kabuki syndrome in paediatrics: Insights in 11 patients

8. Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohort

9. P1451: PUBERTAL DEVELOPMENT OF TRANSFUSION DEPENDENT THALASSEMIA PATIENTS AT THE ERA OF ORAL CHELATION WITH DEFERASIROX: RESULTS OF THE FRENCH NATIONAL REGISTRY NATHALY

10. Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study

11. Molecular and clinicopathologic characterization of pediatric histiocytoses

14. Molecular and clinicopathologic characterization of pediatric histiocytoses.

15. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma – An Anglo-French collaborative report

16. Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement

19. Epstein-Barr Virus in Childhood and Adolescent Classic Hodgkin Lymphoma in a French Cohort of 301 Patients

20. Hematological Involvement in Childhood Langerhans Cell Histiocytosis: A Cohort Study of 303 Patients

21. Epstein Barr Virus in childhood and adolescent classical Hodgkin lymphoma in a French cohort of 301 patients

22. Should treatment of ALK‐positive anaplastic large cell lymphoma be stratified according to minimal residual disease?

23. Liste des collaborateurs

24. Thymus and mediastinal node involvement in childhood langerhans cell histiocytosis: Long-term follow-up from the French national cohort

25. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE)

26. Childhood hodgkinʼs lymphoma, non-hodgkinʼs lymphoma and factors related to the immune system: The escale study (SFCE)

27. Long‐term follow‐up of children with risk organ‐negative Langerhans cell histiocytosis after 2‐chlorodeoxyadenosine treatment

28. De novo missense variants in theRAP1Bgene identified in two patients with syndromic thrombocytopenia

29. IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma

30. Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies

33. Deciphering the Causal Diagnosis of Hydrops Fetalis or Unexplained Fetal Anemia Using Targeted Next Generation and Exome Sequencing

35. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study

36. De novo missense variants in the RAP1B gene identified in two patients with syndromic thrombocytopenia.

37. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study

38. Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience

39. Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups

40. IL10RA modulates crizotinib sensitivity in NPM1-ALK+anaplastic large cell lymphoma

41. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.

42. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy

44. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30‐year nationwide cohort of 1478 patients under 18 years of age

45. Lethal ALAS2 mutation in males X-linked sideroblastic anaemia.

46. Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in Children and Adolescents : Retrospective Study from Sfce and Ukccssg

Catalog

Books, media, physical & digital resources